Wall Street pushback against relaxin player Tectonic Therapeutic Inc. was sharp, but a trial design that differs could save the drug from the fate of Astrazeneca plc’s long-acting relaxin-2 analogue, AZD-3427, which the pharma giant has “removed from phase II,” where it was being tested in a trial called Re-phire, because of less than ideal efficacy.
Investigators described preclinical data for AZD-5462 (Astrazeneca plc/Mitsubishi Tanabe Pharma Corp.), a novel oral agonist of the relaxin family peptide receptor 1 (RXFP1), being developed for the treatment of cardiorenal disease.
